{"disease":{"id":"breast-cancer-hr-her2-early-stage","name":"breast cancer hr her2 early stage"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07484763","title":"Predicting Recurrence in HR+/HER2- Early Breast Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Shengjing Hospital","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}